Plavix Pharmacogenomic Label Update May Help Lilly With Effient Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol/Sanofi blockbuster label was quietly updated two months ago to include precautionary statement and pharmacogenomic data about non-responders to Plavix. That label dovetails with Lilly's initial positioning of prasugrel.
You may also be interested in...
Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch
Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel
Circulation study shows prasugrel metabolism unaffected by marker for Plavix non-response. Data won’t surprise FDA, but what will be the regulatory response?